Table 3 Tumour characteristics associated with “Over St Gallen” treatment.
Variable | Category | n Over St Gallen/n included | RRR (95% CI) | p |
|---|---|---|---|---|
Age | (each 10 years) | 0.70 (0.62–0.81) | < 0.001 | |
Pathological stage | 0 | 0/36 | – | – |
I | 56/519 | 1 (ref.) | – | |
II | 187/597 | 4.15 (2.90–5.94) | < 0.001 | |
Grade of differentiation | I (well differentiated) | 69/260 | 1 (ref.) | – |
II (moderately differentiated) | 115/367 | 1.26 (0.84–1.89) | 0.27 | |
III (poorly differentiated) | 10/222 | 0.09 (0.04–0.19) | < 0.001 | |
Missing | 49/303 | 1.03 (0.55–1.92) | 0.94 | |
Histological type | Ductal | 200/918 | 1 (ref.) | – |
Lobular | 20/82 | 1.72 (0.94–3.17) | 0.08 | |
Papilar | 1/16 | 0.31 (0.04–2.53) | 0.28 | |
Others | 22/136 | 0.87 (0.50–1.50) | 0.61 | |
Progesterone receptors | Negative | 14/262 | 1 (ref.) | – |
Positive | 229/887 | 8.12 (4.41–14.9) | < 0.001 | |
Missing | 0/3 | – | – | |
Oestrogen receptors | Negative | 12/155 | 1 (ref.) | – |
Positive | 231/996 | 5.71 (2.97–11.0) | < 0.001 | |
Missing | 0/1 | – | – | |
HER2 receptors | Negative | 224/953 | 1 (ref.) | – |
Positive | 19/199 | 0.46 (0.26–0.81) | 0.007 | |
Intrinsic subtype | Luminal A-like | 221/687 | 1 (ref.) | – |
Luminal B-like | 12/324 | 0.07 (0.04–0.13) | < 0.001 | |
HER2 positive (non-luminal) | 7/52 | 0.30 (0.11–0.83) | 0.02 | |
Triple negative (ductal) | 3/89 | 0.03 (0.01–0.11) | < 0.001 |
